Trial Profile
Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytoplasmic activated PD 1anti CD19 CAR transduced T cells - Pregene ShenZhen Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma
- Focus Adverse reactions
- 05 Jun 2018 New trial record